Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

NRX Pharmaceuticals (NRXP) Change in Account Payables (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Change in Account Payables for 2 consecutive years, with $13000.0 as the latest value for Q4 2025.

Quarterly Change in Account Payables rose 100.13% to $13000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $113000.0 through Dec 2025, up 102.17% year-over-year, with the annual reading at $113000.0 for FY2025, 102.17% up from the prior year.
Change in Account Payables for Q4 2025 was $13000.0 at NRX Pharmaceuticals, down from $601000.0 in the prior quarter.
The five-year high for Change in Account Payables was $2.1 million in Q2 2024, with the low at -$10.2 million in Q4 2024.